CHROMATOGRAPHIC METHOD OF SEPARATION OF RADIONUCLIDE LUTETIUM-177, CARRIER FREE FROM MACRO-QUANTITIES OF YTTERBIUM
##plugins.themes.academic_pro.article.sidebar##
Downloads
##plugins.themes.academic_pro.article.main##
Abstract
Currently, promising direction of development of modern oncology is a radionuclide therapy using radiopharmaceuticals sighting direction, ie the targeted effect on tumor tissue. For this purpose, suitable radionuclide 177Lu, possessing optimal nuclear-physical characteristics with an average half-life (T1/2 = 6,7 days); acceptable energy β-particles (maximum 0,5 MeV), which allows to destroy small tumors and metastasis without affecting the healthy tissues; concomitant soft γ-radiation with sufficient energy for imaging. Targeted exposure helps to get rid of neuroendocrine tumors, thyroid cancers, some types of brain cancer, and prostate cancer, and so on.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019 Monday, December 16, 2019, National Cancer Institute – Shady Grove, Maryland
- Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. – J. Med. Radiat. Sci. 2017, 64(1), Р. 52-60.
- Кодина Г.Е., Красикова Р.Н. Методы получения радиофар м ацев тиче ских препара т ов и радио -нуклидных генераторов для ядерной медицины. М., 2014. С. 60.
- В.А. Тарасов, Е.Г. Романов, Р.А. Кузнецов. СРАВНИТЕЛЬНЫЙ АНАЛИЗ СХЕМ РЕАКТОРНОЙ НАРАБОТКИ ЛЮТЕЦИЯ-177. Известия Самарского научного центра Российской академии наук, 2013, т. 15, №4(5), С. 1084-1090.
- Отчет НИР Института Ядерной Физики Академии Наук Республики Узбекистан. № Гос рег. 01.2000.09698, Ташкент 2002, 40 с.